Kyowa Hakko USA used this year’s SupplySide West to promote its on-trend ingredients for both immune and cognitive health. Featured were IMMUSE™ postbiotic and Cognizin® citicoline branded ingredients.

IMMUSE™ postbiotic is a clinically researched immune activator supported by nearly 30 published studies, including 14 human trials. IMMUSE™ delivers a breakthrough approach to comprehensive immune support through a novel method of action that utilizes a rare but key type of immune cells called plasmacytoid dendritic cells (pDC), which have been shown to activate cells that are pivotal to immune support, such as NK, Killer-T, Helper-T, and B cells.*

Heather Moday (pictured), MD, author of "The Immunotype Breakthrough," spoke at SupplySide West and assisted members of the audience in determining their personal immunotypes. Moday explained how immunotypes can be used to identify individuals’ most effective methods of immune support and how IMMUSE™’s unique mode of action can support that process – a mode of action that was discovered by Kyowa Hakko's parent company Kirin Holdings Co., Ltd.

“Our body registers all stressors, including work, financial, and family stress just to name a few, in the same way as a real physical threat,” Moday shared during her presentation. “When you add up all of the small stressors that are constantly triggering our fight-or-flight response, it leads to changes in our immune system.”

Cognizin®, Kyowa Hakko’s branded form of citicoline, is a potent brain health nutrient and nootropic that has been shown through extensive clinical studies and human trials to support mental energy, focus, memory, and attention.* While many other cognitive health ingredients only enhance brain  performance, citicoline increases an important substance in the brain called phosphatidylcholine that offers multi-faceted benefits. 

Cognizin® is an innovative, pure form of citicoline.

At SupplySide West, Kyowa Hakko emulated a clinical study that targeted e-gamers and was conducted by neuropsychologists using a variety of tests simulating cognitive functions and keyboard actions, including a finger tap test. Tradeshow attendees could participate in the “Tap Challenge,” available through an app, to see how quickly they could tap a button over a 20-second timeframe.

“We debuted this app at SxSW and it was a hit,” said Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc. “We had the same positive response at SupplySide West, and we were excited to bring the benefits of Cognizin® to life for the researchers and innovators behind the next big nutraceuticals and functional foods and beverages.”

Cognizin® is currently available in more than 200 products on the market globally.

Kyowa Hakko will continue educating the industry and consumers on the benefits of IMMUSE™ and Cognizin® throughout 2023 alongside its other branded ingredients, including Setria® Glutathione, Pantesin® Pantethine, VELOX® Patented Performance Blend, and EYEMUSE™ Lacticaseibacillus paracasei KW3110.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

About Kyowa Hakko USA
Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food products. For more information, visit Kyowa-USA.com.